Restructuring, Rights Issue, and UK sales outlook

in addition to my question regarding "who participate in issuance? " - see below - is the management in UK participating ? ( I figure Devika is key personel for success in the UK hence important to keep her at B+ team )

Regarding the allready annonced issuance of new shares and the 50% prebooked interest
Can you unveil the split in commitment between :

1/ management
2/ current institutions involved
3/ bigger private investors / retail

What are the % costs, of providing a full CST treatment course, by Ayla, per patient, for the users of Ayla, compared to providing CST by traditional ways, is it fx 75%, for a full CST treatment course?

Can you clearify on the webinar 3.2.2025, what "short term" sales mean, and what is left to do, before finalizing first sales in UK, fx receiving payments, board approval from buyers, or installing Ayla?

Can you reveal how close first UK sale or sales are, where 0 is pending contact, and 100 is finalized agreements, with payment and Ayla start up dates being set? Or if you have a step-by-step visualisazion, kindly show where, the ongoing dialogues are, at this moment?

We all know that shareprice for the moment is 100% related to sales development and I am not asking Brain+ to have an opinion about current shareprice and the market mechanism - BUT
how focused are you for the moment at getting an UK order announced so that the upcoming new issuance and funding will be at a better level than what is possible at current potential funding level ?

Can you please give specific examples to first how you current use AI and Automation to enhance operation and development, and secondly how you plan on going about this in the future?

What's the conversion development now, in terms of direct clickable interest, compared to before the new website?

What long term content marketing activities are you working on (especially for UK)?